Bristol-Myers Squibb is set to present new data on Orencia (abatacept) at the European League Against Rheumatism 2012 Congress, following the results of clinical research into the drug.
Orencia is a lyophilized powder for intravenous infusion or a solution for an under the skin injection.
The findings will be presented in the form of a head-to-head study comparing two biologic drugs for the treatment of rheumatoid arthritis.
The results of a the Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects With Background Methotrexate (Ample) study will also be outlined.
This was a randomised study that compared the efficacy of Orencia SC versus Humria on a background of methotrexate in adult, biologic naïve patients with moderate to severe rheumatoid arthritis.
"The data being presented highlight Bristol-Myers Squibb's continued commitment to expanding our understanding of the efficacy and safety of Orencia," commented senior vice-president for global development and medical affairs at Bristol-Myers Squibb Brian Daniels MD.